Costimulatory blockade via the CTLA-4–Ig fusion protein abatacept is beneficial in patients with early-onset type 1 diabetes, but some individuals benefit more than others. A new study reports that the pretreatment abundance of T follicular helper (TFH) cells could predict clinical responses to abatacept.

中文翻译：

---

循环的TFH细胞可作为T1D早期治疗干预的标志物。

通过CTLA-4-Ig融合蛋白abatacept进行的共刺激封锁对早期发作的1型糖尿病患者是有益的，但有些人比其他人受益更多。一项新研究报告称，预处理的T卵泡辅助细胞（TFH）丰富可以预测对abatacept的临床反应。